CML is a clonal myeloproliferative disease which typically presents in chronic phase (CP), in which malignant progenitor cells proliferate rapidly but retain much of their ability to differentiate, with the disease later evolving to accelerated phase/blast crisis. Even after the introduction of ...
Lassche G, van Helvert S, Eijkelenboom A, Tjan MJH, Jansen EAM, van Cleef PHJ, Verhaegh GW, Kamping EJ, Grünberg K, van Engen-van Grunsven ACH, Ligtenberg MJL, van Herpen CML. Identification of fusion genes and targets for genetically matched therapies in a large cohort of salivary glan...
Even within a particular form of hematologic malignancy (e.g., AML, ALL, CML, CLL) there is significant variability in response to therapy among patients. For example, in acute myeloid leukemia (AML), response to standard chemotherapy (idarubicin+ara-C) varies significantly between patients, ...
How do the causes of diarrhea for ETEC and EPEC serotypes differ? What is the physiological reasoning behind inflammatory bowel disease leading to colon cancer? How does a Philadelphia chromosome cause CML (chronic myelogenous leukemia)? Explain Brown Syndrome, including its causes and ef...
A unique advantage of targeted RNAseq is the ability to resolve alternative fusion gene isoforms that may inform clinical action. For example, across the five CML patients, we identified two previously describedBCR-ABL1isoforms that were associated with disparate responses to imatinib treatment47,48(...
doi:10.1093/fampra/cml068Bamford ClaireEccles MartinSteen NickRobinson LouiseFamily PracticeBamford, C., Eccles, M., Steen, N., Robinson, L., 2007. Can primary care record review facilitate earlier diagnosis of dementia? Fam. Pract. 12, 183-192....
Second-order strategy, e.g., Collective Multi-Label Classifier (CML) [17], Ranking Support Vector Machine (Rank-SVM) [18], and Calibrated Label Ranking(CLR) [19], considers correlations between a pair of labels in the learning process. For multi-label data with m labels, CLR makes m(...
progression [22] and led to the development of several oncogenes-targeting therapies, including the c-KIT inhibitor Imatinib, the anti-HER2 agent Trastuzumab and the ALK inhibitor Crizotinib for the treatment of chronic myeloid leukemia (CML), non-small cell lung cancer (NSCLC) and breast cancer...
oMxaidgenectoicn-ptrlaasstmaogneinctisn)v, easntidgaaticotinvserefvlueoarleedsctehnetirainmdprXo-vraeyd pcloanstmraosnticfocrhamraacgtnereitsitciaclslyingcuoimdepdariasnodn awmitphlisfpiehderpichaoltoptahretircmleasl atshearasipginesifi[c1a8n1t].reIdn-sahdifdtitiinonU,Vt-hVisis raebsseoarr...
IIttss rruunnnniinngg pprroocceessss iiss sshhoowwnnasasfoflolollwosw: sF:irFsitrlys,tltyh,etmheicrmocicornotcroonlletrrohllaerrdwhaarrdewmaordeumle,oidnucllue,diinngcluthdeinAgDtshaemAplDingsammopdluinleg, cmloocdkumle,odcluolcek, amnoddSuelrei,aal nPderSipehriearlaPl eInritpehrfearcael ...